Category Archives: Syndicated

Sept 14 (Reuters) - CVC-backed Bamboo Insurance Services is targeting a valuation of up to $3.13 billion in its U.S. initial public offering, the company revealed in a filing on Monday. The Midvale, U...

By Kristina Cooke and Ben Kellerman Sept 14 (Reuters) - Immigration arrests in the U.S. have soared in recent months, aided by more local law enforcement cooperation with ICE, increased use of technol...

By Friederike Heine BERLIN/BRUSSELS/LONDON, Sept 14 (Reuters) - Germany on Monday said halting the development of artificial intelligence systems was not a "viable option" for Europe, as the region's ...

By Nivedita Balu and Promit Mukherjee TORONTO, Sept 14 (Reuters) - Canadian Prime Minister Mark Carney welcomes dozens of global investors to Toronto this week, hoping to lure investments for more tha...

WOLGAST, Germany, Sept 14 (Reuters) - A drone strike on a train near the Ukraine-Poland border is a calculated escalation by Russia's President Vladimir Putin to instil fear in Europe, German Defence ...

(Corrects correspondent name in reporting line; no change in text) AMMAN, Sept 14 (Reuters) - Eleven people were injured in an ammonia gas leak at an industrial complex in Jordan's southern city of Aq...

By Feras Dalatey , Mahmoud Hasano and Firas Makdesi ALEPPO, Syria, Sept 14 (Reuters) - A sharp rise in fuel prices at the weekend has sparked protests across Syria, in the country's most widespread de...

By Marc Jones LONDON, Sept 14 (Reuters) - The AI-linked rally that has seen world stock markets soar over the last two years is showing growing signs of vulnerability, global central bank umbrella bod...

By Kamal Choudhury and Puyaan Singh Sept 14 (Reuters) - Definium Therapeutics said on Monday its LSD-based treatment reduced symptoms of generalized anxiety disorder in a second successful late-stage ...

By Foo Yun Chee BRUSSELS, Sept 14 (Reuters) - Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40...